Rene Sindlev is Director & 10% Owner at Enochian Biosciences Inc (ENOB). They have made 10 open-market trades across 1 company since 2017, most recently 2024-02-20.
CIK 0001709513
Unrated. We grade insiders only on stock they chose to buy on the open market. Grants, option exercises and vesting say nothing about timing, so they don't count — which is why someone can file often and still have no grade. It isn't a bad sign: unrated buys beat every graded tier below A.
10 open-market purchases totalling $3.8M since 2017, never a sale. Across 10 scored buys the stock is down 24.5% at ninety days, and 28.3 points behind the S&P over the same stretch.
10 scored purchases · one row per filing · discretionary only
| 7d | 30d | 90d | |
|---|---|---|---|
| Accuracy | 10% | 10% | 10% |
| Avg Move | -11.5% | -21.3% | -24.5% |
| Alpha | -12.6% | -24.0% | -28.3% |
| Scored | 10 | 10 | 10 |
| Ticker | Type | Traded | Filed | Price | Value | 7d Stock | 30d Stock | 90d Stock |
|---|---|---|---|---|---|---|---|---|
| ENOB | BUY | 2022-05-18 | 2022-05-20 | $8.00 | $2.0M | -40.7% | -48.8% | -61.7% |
| ENOB | BUY | 2019-06-04 | 2019-06-06 | $6.70 | $211K | -15.9% | -20.5% | -23.4% |
| ENOB | BUY | 2019-06-03 | 2019-06-05 | $6.70 | $268K | -12.4% | -24.2% | -24.7% |
| ENOB | BUY | 2019-05-29 | 2019-06-05 | $6.60 | $132K | -12.4% | -24.2% | -24.7% |
| ENOB | BUY | 2019-05-28 | 2019-06-05 | $6.61 | $239K | -12.4% | -24.2% | -24.7% |
| ENOB | BUY | 2019-05-24 | 2019-06-05 | $6.25 | $31K | -12.4% | -24.2% | -24.7% |
| ENOB | BUY | 2019-05-22 | 2019-05-24 | $5.76 | $3K | -5.4% | -22.0% | -28.8% |
| ENOB | BUY | 2019-05-21 | 2019-05-23 | $5.75 | $115K | -1.1% | -20.9% | -28.2% |
| ENOB | BUY | 2018-12-27 | 2018-12-28 | $8.00 | $744K | +20.1% | -5.6% | +0.6% |
| ENOB | BUY | 2018-05-21 | 2018-11-07 | $5.38 | $7K | -22.4% | +1.8% | -4.2% |
Grouped by shared companies and similar filing behaviour. This is a similarity measure, not a ranking or a performance signal.